Cargando…
Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma
PURPOSE: Pazopanib has been approved for treating soft tissue sarcomas (STS) after chemotherapy. We aimed to evaluate the prognostic factors, clinical outcomes, and tolerability of pazopanib in patients with STS. PATIENTS AND METHODS: Forty-five patients treated between June 2015 and August 2019 wer...
Autores principales: | Alshamsan, Bader, Badran, Ahmad, Alshibany, Aisha, Maraiki, Fatma, Elshenawy, Mahmoud A, Elhassan, Tusneem, Atallah, Jean Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414075/ https://www.ncbi.nlm.nih.gov/pubmed/34512015 http://dx.doi.org/10.2147/CMAR.S323499 |
Ejemplares similares
-
Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer
por: Alshamsan, Bader, et al.
Publicado: (2021) -
Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial
por: Bazarbashi, Shouki, et al.
Publicado: (2023) -
Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma
por: Alshamsan, Bader, et al.
Publicado: (2020) -
Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California
por: Seto, Tiffany, et al.
Publicado: (2019) -
Pazopanib: Approval for Soft-Tissue Sarcoma
por: Nguyen, Diana T., et al.
Publicado: (2013)